The new indications of the antidepressant drug Brintellix of Lingbei pharmaceutical have been supported by CHMP. This drug will soon become the first antidepressant approved in the EU to improve the cognitive function of patients with depression. The new indications are based on the results of the connecting test. The results show that when compared with placebo, vortioxetine and Lilly's antidepressant competitive product duloxetine can better improve various cognitive indexes of patients.
People with severe depression usually report a series of cognitive symptoms, including obvious difficulties in thinking, attention, and memory of new information, which can damage patients' self-confidence and lead to social disharmony. Although cognitive problems have been well recognized in other mental diseases such as schizophrenia, there are few studies on their impact on depression.
हमें खुशी है कि vortioxetine को CHMP से सकारात्मक टिप्पणियां मिलीं, विशेष रूप से अधिकांश रोगियों के उपचार के परिणाम को प्रभावित करने में संज्ञानात्मक हानि की स्थिति, लिंगबी अनुसंधान और विकास के निदेशक पेडरसन ने कहा। संज्ञानात्मक विकारों को संबोधित करने में हमने जो उत्साहजनक डेटा देखा है, वह हमें विश्वास दिलाता है कि वोर्टियोक्सेटीन में कई रोगियों को उनके अवसाद का इलाज करने में मदद करने की क्षमता है।
Votexetine has been listed in the United States for only more than a year, and it is gradually lifted in the whole EU. Last September, it was listed in Denmark, Lingbei's hometown. It is reported that this drug is the fastest-growing new antidepressant in the United States in the past three years. This drug is jointly listed by Lingbei and Takeda in the United States.
लिंगबेई के लिए यह अच्छी खबर है क्योंकि इसे अपने पुराने एंटीडिप्रेसेंट इडप्रेम के पेटेंट की समाप्ति के बाद छोड़े गए प्रभाव के लिए नई दवाओं की आवश्यकता है। Yidepulum कई बिलियन डॉलर की वार्षिक बिक्री वाली एक ब्लॉकबस्टर दवा थी, जो जेनेरिक दवाओं की प्रतिस्पर्धा से प्रभावित हुई है।
Votexetine sold 188 million kroner (27 million) in six EU markets last year, compared with 83 million kroner in the fourth quarter alone, so it still has some ways to catch up with Idem. Although Idprem no longer has a market franchise, it still sold 4.6 billion kroner. The Danish company also has long-acting schizophrenic drug aripiprazole and an alcohol addiction treatment drug nalmefene, which can help vortioxetine increase the company's revenue again.